Prothena Past Performance
Past criteria checks 0/6
Prothena has been growing earnings at an average annual rate of 23.7%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 56.5% per year.
Earnings growth rate
EPS growth rate
|Biotechs Industry Growth||7.2%|
|Revenue growth rate||56.5%|
|Return on equity||-21.0%|
|Last Earnings Update||31 Mar 2023|
Recent past performance updates
Earnings and Revenue History
Quality Earnings: 0Y3M is currently unprofitable.
Growing Profit Margin: 0Y3M is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 0Y3M is unprofitable, but has reduced losses over the past 5 years at a rate of 23.7% per year.
Accelerating Growth: Unable to compare 0Y3M's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0Y3M is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7%).
Return on Equity
High ROE: 0Y3M has a negative Return on Equity (-20.99%), as it is currently unprofitable.